Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246 | 0.86 | — | — | |
| Potassium Ion SCHEMBL4796478 | 0.84 | — | — | |
| SCHEMBL9705778 | 0.82 | ALDH1A1 (0.39) | LMNA | |
| SCHEMBL9934168 | 0.67 | TSHR (0.41) | TSHRGPR35LMNAMAPT | |
| Nitric Acid SCHEMBL28348863 | 0.62 | TSHR (0.62) | TSHRGPR35LMNA | |
| SCHEMBL7759714 | 0.60 | — | — | |
| SCHEMBL14964134 | 0.60 | NOTUM (0.64) | NOTUM | |
| SCHEMBL29002968 | 0.60 | — | — | |
| SCHEMBL1097495 | 0.59 | TSHR (1.00) | TSHRGPR35LMNA | |
| SCHEMBL63265 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | QUADREL S.R.L. (IT) | 2023-11-16 | — | — | US | claimed |
| EP-4216960-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | Quadrel S.r.l. (IT) | 2023-08-02 | — | — | EP | claimed |
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | QUADREL S.R.L. (IT) | 2023-11-16 | — | — | US | disclosed |
| EP-4216960-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | Quadrel S.r.l. (IT) | 2023-08-02 | — | — | EP | disclosed |
| US-RE39355-E1 | Preparation of human IGF via recombinant DNA technology | GENETECH, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-6465235-B1 | OXIDATION, HEAT AND ALKALI RESISTANCE | GENENCO INTERNATIONAL, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6331414-B1 | GENERATING INSULIN LIKE GROWTH FACTOR; CONSTRUCT EXPRESSION VECTOR, TRANSFORM PROKARYOTIC CELL, CULTURE CELLS, RECOVER INSULIN LIKE GROWTH FACTOR | GENENTECH, INC. | 2001-12-18 | — | — | US | disclosed |
| US-6331609-B1 | FUSION PROTEIN; FOR USE IN TREATMENT OF SOMATOTROPIN DEFECTS | GENENTECH, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-0130756-B2 | Procaryotic carbonyl hydrolases, methods, DNA, vectors and transformed hosts for producing them, and detergent compositions containing them | GENENCOR INT (US) | 2000-06-28 | — | — | EP | disclosed |
| US-5972682-A | Enzymatically active modified subtilisins | GENENCOR INTERNATIONAL, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5955340-A | DNA CODING POLYPEPTIDE WITH ALTERED HEAT OXIDATION AND ALKALI RESISTANCE, SUBSTRATE SPECIFICITY AND ENZYME KINETICS | GENENCOR INTERNATIONAL, INC. (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0128733-B1 | HUMAN INSULIN-LIKE GROWTH FACTOR (IGF) PRODUCED FROM A RECOMBINANT HOST, PROCESS, EXPRESSION VECTOR AND RECOMBINANT HOST THEREFOR, AND IGF-CONTAINING PHARMACEUTICAL COMPOSITION | GENENTECH, INC. (US) | 1992-05-06 | — | — | EP | disclosed |
| US-5021550-A | Method for preventing deletion sequences in solid phase synthesis | THOMAS JEFFERSON UNIVERSITY (US) | 1991-06-04 | — | — | US | disclosed |
| US-4940661-A | Metallothionein transcription control sequences and use thereof | GENENTECH, INC. (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0357157-A2 | Procaryotic carbonyl hydrolases and mutants thereof, and methods for producing and using them | GENENCOR INTERNATIONAL, INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4760025-A | Modified enzymes and methods for making same | GENENCOR, INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0247647-A1 | DNA mutagenesis method | GENENTECH, INC. (US) | 1987-12-02 | — | — | EP | disclosed |
| EP-0246678-A1 | Bacillus incapable of excreting subtilisin or neutral protease | GENENCOR INTERNATIONAL, INC. (US) | 1987-11-25 | — | — | EP | disclosed |
| EP-0130756-A1 | Procaryotic carbonyl hydrolases, methods, DNA, vectors and transformed hosts for producing them, and detergent compositions containing them | GENENCOR INTERNATIONAL, INC. (US) | 1985-01-09 | — | — | EP | disclosed |
| EP-0128733-A1 | Human insulin-like growth factor (IGF) produced from a recombinant host, process, expression vector and recombinant host therefor, and IGF-containing pharmaceutical composition | GENENTECH, INC. (US) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | PIGO, PIGS, AGPS | TSHR 3524/4885NOTUM 221/4885GPR35 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.